黄色小说视频-日本少妇高潮抽搐-国内自拍av-天堂中文资源在线-蜜桃视频在线入口www-91久久综合-亚洲视频在线一区-日日夜夜拍-国产精品资源在线观看-欧美激情国产精品免费-人妻少妇久久中文字幕-成人免费无码大片a毛片-香蕉污视频在线观看-日本电影成人-国内精品久久99人妻无码

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購物車 1 種商品 - 共0元
當前位置: 首頁 > ATCC代理 > HBEC3-KT
最近瀏覽歷史
聯系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮海區莊市街道興莊路9號
  • 創e慧谷42號樓B幢401室
HBEC3-KT
HBEC3-KT
規格:
貨期:
編號:B205492
品牌:Mingzhoubio

標準菌株
定量菌液
DNA
RNA

規格:
凍干粉
斜面
甘油
平板


產品名稱 HBEC3-KT
商品貨號 B205492
Organism Homo sapiens, human
Tissue lung, bronchial
Cell Type epithelial
Product Format frozen
Morphology epithelial, packed cuboidal
Culture Properties adherent
Biosafety Level 2  [Cells immortalized by CDK4 and hTERT and contain SV40 promoter sequences]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease normal
Age 65
Gender female
Applications

HBEC3-KT cells are normal human bronchial epithelial cells immortalized with CDK4 and hTERT.  The immortalized HBEC3-KT cells do not form colonies in soft agar, nor do they form tumors in mice (RefRamirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64(24):9027-9034, 2004. PubMed: 15604268).  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs) are not sufficient to confer a full malignant phenotype on HBEC3-KT. These additional genetic changes, commonly found in human lung cancer, progress the HBEC3-KT cells partially, but not completely, toward malignancy (RefSato M, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66(4): 2116-2128, 2006. PubMed: 16489012). 

Extended lifespan (RefRamirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64(24):9027-9034, 2004. PubMed: 15604268), multi-potent differentiation capacity in three-demensional models (RefDelgado O, et al. Multipotent capacity of immortalized human bronchial epithelial cells. PLoS ONE. 6(7): e22023, 2011. PubMed: 21760947), and drug-sensitivity tests (paclitaxel, carboplatin, pemetrexed, cisplatin, gemcitabine, etc.) have been reported for the HBEC3-KT cells (RefSato M, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol. Cancer Res. 11(6): 638-650, 2013. PubMed: 23449933).

Storage Conditions liquid nitrogen vapor phase
Karyotype Cytogenetic analysis was performed on G-banded metaphase cells from the human cell line HBEC3-KT, and demonstrated mixed population of clones with near-diploid or tetraploid abnormal female karyotypes. Unbalanced translocations der(16)t(5;16)(q11.2;q24) and der(13)t(8;13)(q13.1;p11.1) as well as an extra copy of chromosome 20 with additional translocation +add(20)(q13.3) are observed in these clones. These aberrations result in partial trisomies of chromosome 5, 8 or 20 which have been found in a previous aCGH microarray analysis of HBEC3-KT (PMID: 15604268)
Images ATCC CRL-4051 Cell Micrograph ATCC CRL-4051 CCSP Expression ATCC CRL-4051 P63 Expression Image
Derivation

The HBEC3-KT cell line was established by infecting primary human bronchial epithelial cell culture with human telomerase (hTERT) and mouse cyclin dependent kinase 4 (CDK4) expressing retrovirus constructs and selecting with Puromycin and G418 as described in PMID: 15604268 (RefRamirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64(24):9027-9034, 2004. PubMed: 15604268).

Clinical Data female
65 years
Antigen Expression Positive for p63 (TP63) and Clara cell 10 (CC10) protein
Complete Growth Medium Airway Epithelial Cell Basal Medium (ATCC PCS-300-030) suplemented with Bronchial Epithelial Cell Growth Kit (ATCC PCS-300-040)
Subculturing Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation solutions for culture vessels of other sizes.

Subculture when the culture is about 70-80% confluent.

  1. Remove and discard spent medium.
  2. Briefly rinse the cells with Dulbecco's Phosphate Buffered Saline (DPBS, ATCC 30-2200), 1 mL / 25 cm2 and discard rinse solution.
  3. Add Trypsin-EDTA, at 1 mL / 25 cm2, for Primary Cells (ATCC PCS-999-003) to the flask. Incubate at 37°C for 4-6 min (until 90% of the cells have detached).
  4. tap flask gently to ensure cells are detached.  Add 2% FBS in DPBS at 1 mL / 25 cm2 to neutralize the trypsin.
  5. Centrifuge cells at 1000rpm for 5 min at room temperature.
  6. Remove supernatant. Resuspend pellet in 6.0 to 8.0 mL Complete Growth Medium.
  7. Count cells, and seed 4.0 x 103 to 6.0 x 103 viable cells/cm2 to new culture vessels.
Medium Renewal: Every 2-3 days.

Note: The cells are sensitive to DMSO and FBS. Ensure that as much as possible is removed after centrifugation, and before seeding into the recommended culture medium.

Cryopreservation 80% complete growth media, 10% DMSO, 10% FBS
Culture Conditions Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile D5S818:         12   
D13S317:       12, 13
D7S820:         8, 12
D16S539:       9, 12
vWA:              15, 17 
Amelogenin:     X
TPOX:              11, 12
CSF1PO:         10, 11
TH01:               9.3
Population Doubling Level (PDL) As part of our quality control, we have tested this cell line for its ability to grow for a minimum of 15 population doublings after recovery from cryopreservation. We have also compared its karyotype, telomerase expression level, growth rate, morphology and tissue-specific markers when first recovered from cryopreservation with that of cells at 10+ population doublings to ensure that there is no change in these parameters and that the cells are capable of extended proliferation.
Name of Depositor John Minna, Shelley Sheridan
References

Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64(24):9027-9034, 2004. PubMed: 15604268

Delgado O, et al. Multipotent capacity of immortalized human bronchial epithelial cells. PLoS ONE. 6(7): e22023, 2011. PubMed: 21760947

Sato M, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol. Cancer Res. 11(6): 638-650, 2013. PubMed: 23449933

Sato M, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66(4): 2116-2128, 2006. PubMed: 16489012

Vaughan MB, et al. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation. 74(4):141-148, 2006. PubMed: 16683984

梅經理 17280875617 1438578920
胡經理 13345964880 2438244627
周經理 17757487661 1296385441
于經理 18067160830 2088210172
沈經理 19548299266 2662369050
李經理 13626845108 972239479